Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index; 8 of the 20 sources its claims cite were checked for support.
Abstract
BACKGROUND: For extended-release drug formulations, effective half-life (t 1/2eff ) is a relevant pharmacokinetic parameter to inform dosing strategies and time to reach steady state. Tacrolimus, an immunosuppressant commonly used for the prophylaxis of organ rejection in transplant patients, is available as both immediate- and extended-release formulations. To the best of our knowledge, the t 1/2eff of tacrolimus from these different formulations has not yet been assessed. The objective of this study was to characterize the t 1/2eff and terminal half-life (t 1/2z ) of an extended-release once-daily tacrolimus formulation (LCPT) and twice-daily immediate-release tacrolimus (IR-Tac). METHODS: A noncompartmental analysis of pharmacokinetic data obtained from a phase 2 study in de novo kidney transplant recipients receiving either LCPT or IR-Tac was conducted. Intensive blood sampling was performed on days 1, 7, and 14, and tacrolimus whole blood concentrations were measured using a validated liquid chromatography with tandem mass spectrometry method. T 1/2eff was estimated using within-participant accumulation ratios. T 1/2z was estimated by linear regression of the terminal phase of the concentration versus time profile. RESULTS: The median accumulation ratios of LCPT and IR-Tac on day 14 were 3.18 and 2.06, respectively.The median (interquartile range; IQR) t 1/2eff for LCPT at day 14 of dosing was 48.4 (37.4-77.9) hours, whereas the t 1/2z was 20.3 (17.6-22.9) hours. For IR-Tac, the median (IQR) t 1/2eff and t 1/2z on day 14 were 12.5 (8.8-23.0) hours and 12.2 (9.2-15.7) hours, respectively. CONCLUSIONS: Consistent with its prolonged release of tacrolimus, LCPT demonstrated a higher accumulation ratio and a longer t 1/2eff compared with IR-Tac. These findings underscore the pharmacokinetic differences between different drug formulations of the same moiety and may help inform dose adjustments for LCPT in kidney transplantation.
Overview
CoChat Summary
TL;DR
This phase 2 pharmacokinetic analysis in de novo kidney transplant recipients found that once-daily LCPT tacrolimus accumulates more and has a much longer effective half-life than twice-daily immediate-release tacrolimus (IR-Tac). The authors conclude that effective half-life better reflects LCPT’s dosing behavior and may help guide dose adjustments in kidney transplantation.
Key findings
- On day 14, the median accumulation ratio was higher with LCPT than IR-Tac: 3.18 vs 2.06.
- For LCPT, median t1/2eff was 48.4 hours (IQR 37.4–77.9) on day 14, while median t1/2z was 20.3 hours (IQR 17.6–22.9).
- For IR-Tac, median t1/2eff and t1/2z on day 14 were similar: 12.5 hours (IQR 8.8–23.0) and 12.2 hours (IQR 9.2–15.7), respectively.
- Based on LCPT’s median t1/2eff of 48.4 hours, the paper estimates 8.1 days (IQR 6.2–13.0) to reach 93.75% of steady state.
Methods
- Noncompartmental pharmacokinetic analysis of data from a phase 2, open-label, randomized study in adult de novo kidney transplant recipients assigned 1:1 to once-daily LCPT or twice-daily IR-Tac.
- Intensive blood sampling on days 1, 7, and 14; tacrolimus whole-blood concentrations measured by validated LC-MS/MS.
- t1/2eff estimated from within-participant accumulation ratios; t1/2z estimated by linear regression of the terminal phase of the concentration-time curve.
Limitations
- The paper states the analysis was in de novo kidney transplant recipients, not stable kidney transplant recipients.
- The phase 2 trial excluded patients with factors affecting tacrolimus pharmacokinetics (for example, interacting medications or liver dysfunction), and genotyping was not performed, so the impact of CYP3A4/5 polymorphisms could not be assessed.
- The paper notes that clinician-driven dose changes meant some participants may not have been at steady state on day 7 or 14, which could have underestimated t1/2eff.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
4 Valid · 2 Not valid · 6 Not checked · 39 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although exhibiting prolonged absorption and multicompartmental pharmacokinetics, t1/2eff has not previously been explored for tacrolimus from LCPT.6,10”
§ Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients > INTRODUCTION
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Results > Pharmacokinetics section (page unavailable) reports a significantly longer Tmax for LCPT than for Prograf, supporting delayed absorption. The Statistical Analysis section (page unavailable) describes noncompartmental analysis and does not assess effective half-life; the paper does not establish multicompartmental pharmacokinetics or that effective half-life had never previously been explored. (LLM, conf=0.82)
- Could not verifycites [10] sourceExperimental — accuracy not yet measured
Our copy of Andrews et al. (2017) is a review of TDM-related pharmacokinetic considerations in kidney transplantation, and none of its retrievable body passages states that tacrolimus shows prolonged absorption or multicompartmental pharmacokinetics, nor discusses an effective half-life (t1/2eff) or whether it had been explored for the prolonged-release formulation (LCPT). The body passages returned cover the controversies of C0 monitoring (Sec. 3.2, p. n/a: 'The large variability in the pharmacokinetics of Tac makes it difficult to predict what drug concentration will be achieved...'), AUC/limited-sampling monitoring (Sec. 3.3), drug-drug interactions (Sec. 3.6), pharmacogenetic monitoring (Sec. 5) and the Expert opinion/article highlights, while the abstract frames only narrow therapeutic index, interpatient variability and alternative biomarkers. Queries on 'prolonged absorption', 'multicompartmental', 'half-life/t1/2eff' and 'once-daily/prolonged-release PK' hit only the reference list (e.g. Staatz & Tett once-daily tacrolimus PK review; Adam et al. prolonged-release tacrolimus; Posadas Salas & Srinivas once-daily tacrolimus), which identifies those works but does not state the claim. Since our copy is complete yet does not address the point, the attribution cannot be checked against it. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In addition, the shorter half-life of tacrolimus among kidney transplant recipients compared with healthy volunteers has also been demonstrated with IR-Tac,13 and a similar observation was made in the current study.”
§ Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients > DISCUSSION
What the sources say
- Could not verifycites [13] sourceExperimental — accuracy not yet measured
Our copy of ASERTAA is a crossover pharmacokinetic study confined to 50 African American kidney transplant recipients on stable IR-Tac or LCPT; the Methods (Study End Points) enumerate the parameters measured — AUC0-24, Cmax, tmax, Cmin/C24, predose concentration, %fluctuation and %swing — with no elimination half-life, and no healthy-volunteer comparator arm exists anywhere in the paper (searched: 'half-life', 'healthy volunteers', 'volunteers', 'elimination t1/2'). The Results (Overall Pharmacokinetics of LCPT and IR-Tac) report only formulation contrasts within recipients (IR-Tac tmax 1.1 h vs LCPT 5.0 h, Cmax ~30% lower with LCPT, bioavailability 32% higher), and the Discussion addresses CYP3A5 genotype effects and conversion dosing, not transplant-versus-volunteer pharmacokinetics. So the claim that a shorter half-life with IR-Tac in kidney transplant recipients relative to healthy volunteers was demonstrated here is neither stated nor contradicted by our copy. (LLM, conf=0.70)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, for certain drugs and/or formulations, such as those with modified release, prolonged absorption, and multicompartment distribution, t1/2z may not accurately reflect how long the drug persists in the body or the actual time required to reach steady state.”
§ Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients > INTRODUCTION
What the sources say
- Partly supportedcites [1] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [2] sourceExperimental — accuracy not yet measured
The Introduction and Discussion (pages unavailable) explain that multicompartment kinetics, absorption rate, and extended-release formulations can make terminal half-life a poor predictor of accumulation during repeated dosing. But the Discussion says terminal half-life describes drug loss after dosing stops, and the passages do not establish that it misrepresents how long a drug persists in the body or the time required to reach steady state. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On days 7 and 14, the median (IQR) Rac values were 2.11 (1.46–2.55) and 2.06 (1.64–3.29), respectively.”
§ Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients > RESULTS > IR-Tac Pharmacokinetics
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For IR-Tac, the median (IQR) t1/2eff and t1/2z on day 14 were 12.5 (8.8–23.0) hours and 12.2 (9.2–15.7) hours, respectively.”
- Also stated in: § IR-Tac Pharmacokinetics · hedged
“The estimated t1/2z of tacrolimus when administered as IR-Tac was comparable to the t1/2eff (12.2 hours (9.2–15.7) and 12.5 hours (8.8–23.0), respectively, at day 14), and each was lower than the t1/2eff for LCPT (48.4 (37.4–77.9) h).”
§ Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients > Abstract > Results:
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § IR-Tac Pharmacokinetics · hedged
27 more claims
Create a free account to see all 51 claims and to verify the 2 references still open.
- It may state two separate claims as one. 10
- Probably not a substantial claim. 13
Citations
Cites
Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
Staatz, C. E., & Tett, S. E. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443100-00001 · Cited by 913
Clinical Pharmacokinetics of Tacrolimus
Venkataramanan, R., Swaminathan, A., Prasad, T., Jain, A., Zuckerman, S., Warty, V., McMichael, J., Lever, J., Burckart, G., & Starzl, T. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529060-00003 · Cited by 808
Self-citationTremblay, S., Nigro, V., Weinberg, J., Woodle, E. S., & Alloway, R. R. (2017) · American Journal of Transplantation · doi:10.1111/ajt.13935 · Cited by 171
Pharmacokinetics and drug interactions of eslicarbazepine acetate
Bialer, M., & Soares‐da‐Silva, P. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03519.x · Cited by 168
Andrews, L. M., Li, Y., De Winter, B. C. M., Shi, Y.-Y., Baan, C. C., Van Gelder, T., & Hesselink, D. A. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1395413 · Cited by 142
Sahin, S., & Benet, L. Z. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9787-9 · Cited by 108
Effective Half‐Life in Clinical Pharmacology
Boxenbaum, H., & Battle, M. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04117.x · Cited by 106
Gaber, A. O., Alloway, R. R., Bodziak, K., Kaplan, B., & Bunnapradist, S. (2013) · Transplantation · doi:10.1097/tp.0b013e3182962cc1 · Cited by 100
Trofe-Clark, J., Brennan, D. C., West-Thielke, P., Milone, M. C., Lim, M. A., Neubauer, R., Nigro, V., & Bloom, R. D. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.07.018 · Cited by 93
Dutta, S., & Reed, R. C. (2006) · Clinical Drug Investigation · doi:10.2165/00044011-200626120-00002 · Cited by 27
Research works printed but not linked: 1
- Nigro, 2013, Improved bioavailability of MELTDOSE once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24 hrs: a scintigraphic and pharmacokinetic evaluation [abstract], Am J Transpl., 13, 335
Cited by
Wolesensky, C. S., Patel, N., Nagaraju, S., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70363 · Cited by 1
Clinical pharmacokinetic characteristics and the food effect of radotinib
Lee, Y., Kim, J., Kang, M., Han, J., Kim, N. Y., Shin, J. S., Park, M. S., Jiang, Q., & Lee, J. I. (2026) · Investigational New Drugs · doi:10.1007/s10637-026-01610-6 · Cited by 1
Guo, J., Feng, S., Feng, Z., et al. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2643032
“Therefore, analyzing the time-course of trough concentrations provides a pragmatic approach to investigate inter-patient variability in tacrolimus accumulation and the timing of steady-state attainment under real-world dosing conditions [21,24].”
Metadata
- Authors
- Momper, J. D., Venkataramanan, R., Jantz, A. S., Cibrik, D. M., Birdwell, K., Nguyen, T., Masters, B. M., & Patel, S. J.
- Affiliations
- University of California San Diego (US)
- University of Pittsburgh (US)
- Henry Ford Health (US)
- The University of Kansas Health System (US)
- Vanderbilt University Medical Center (US)
- Veloxis Pharmaceuticals, Inc. (United States) (US)
- Corresponding author
- Momper, Jeremiah D.
- Nguyen, Tk
- ORCID
- Venue
- Therapeutic Drug Monitoring
- Published
- 2024-10-24
- Volume
- 47
- Issue
- 1
- Pages
- 169-173
- ISSN
- 0163-4356 (ISSN-L)
- 1536-3694
- PMC
- PMC11702898
- OpenAlex
- W4403718850
- Cited by
- 3
- References
- 13
- Citations by year
- 2026: 2 · 2025: 1
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Therapeutic Drug Monitoring (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- tacrolimus, effective half-life, sustained-release formulation, immediate-release formulation, accumulation ratio, time to steady state, kidney transplantation, immunosuppression, pharmacokinetics, drug formulation comparison, dose adjustment, whole blood concentration, liquid chromatography-tandem mass spectrometry, non-compartmental analysis, rejection prophylaxis, drug release rate, dose proportionality, pharmacovigilance
- MeSH terms
- Administration, Oral, Adult, Aged, Delayed-Action Preparations, Female, Half-Life, Humans, Immunosuppressive Agents, Male, Middle Aged, Kidney Transplantation, Tacrolimus, Tandem Mass Spectrometry, Transplant Recipients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients. https://app.cochat.ai/papers/10.1097/ftd.0000000000001270
- The paper
- Momper, J. D., Venkataramanan, R., Jantz, A. S., Cibrik, D. M., Birdwell, K., Nguyen, T., Masters, B. M., & Patel, S. J. (2025). Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients. Therapeutic Drug Monitoring. https://doi.org/10.1097/ftd.0000000000001270
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.